Literature DB >> 27741368

Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.

Youn Jin Choi1,2, Je-Keun Rhee3, Soo Young Hur4, Min Sung Kim1, Sung Hak Lee5, Yeun-Jun Chung6,7, Tae-Min Kim3,8, Sug Hyung Lee1,2.   

Abstract

Intraindividual tumoural heterogeneity (ITH) is a hallmark of solid tumours and impedes accurate genomic diagnosis and selection of proper therapy. The aim of this study was to identify ITH of ovarian high-grade serous carcinomas (OSCs) and to determine the utility of ascitic cancer cells as a resource for mutation profiling in spite of ITH. We performed whole-exome sequencing, copy number profiling and DNA methylation profiling of four OSC genomes by using multiregional biopsies from 13 intraovarian lesions, 12 extraovarian tumour lesions (omentum/peritoneum), and ascitic cells. We observed substantial levels of heterogeneity in mutations and copy number alterations (CNAs) of the OSCs. We categorized the mutations into 'common', 'shared' and 'private' according to the regional distribution. Six common, eight shared and 24 private mutations were observed in known cancer-related genes. Common mutations had a higher mutant allele frequency, and included TP53 mutations in all four OSCs. Region-specific chromosomal amplifications and deletions involving BRCA1, PIK3CA and RB1 were also identified. It is of note that the mutations detected in ascitic cancer cells represented 92.3-100% of overall somatic mutations in the given case. Phylogenetic analyses of ascitic genomes predicted a polyseeding origin of somatic mutations in ascitic cells. Our results demonstrate that, despite ITH, somatic mutations, CNAs and DNA methylations in both 'common' category and cancer-related genes were highly conserved in ascitic cells of OSCs, highlighting the clinical relevance of genome analysis of ascitic cells. Ascitic tumour cells may serve as a potential resource for discovering somatic mutations of primary OSC with diagnostic and therapeutic relevance.
Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  ascites; high-grade serous carcinoma; intra-individual tumoural heterogeneity; metastasis; multiregion sequencing; ovarian cancer; phylogeny

Mesh:

Substances:

Year:  2016        PMID: 27741368     DOI: 10.1002/path.4819

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  19 in total

1.  Intratumoral Heterogeneity of Frameshift Mutations of GLI1 Encoding a Hedgehog Signaling Protein in Colorectal Cancers.

Authors:  Ju Hwa Lee; Sang Yong Song; Min Sung Kim; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2017-06-29       Impact factor: 3.201

2.  Intratumoral Heterogeneity of Somatic Mutations for NRIP1, DOK1, ULK1, ULK2, DLGAP3, PARD3 and PRKCI in Colon Cancers.

Authors:  Eun Ji Choi; Ju Hwa Lee; Min Sung Kim; Sang Yong Song; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2017-08-26       Impact factor: 3.201

Review 3.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

4.  Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.

Authors:  Britta Weigelt; Iñaki Comino-Méndez; Ino de Bruijn; Lei Tian; Jane L Meisel; Isaac García-Murillas; Charlotte Fribbens; Ros Cutts; Luciano G Martelotto; Charlotte K Y Ng; Raymond S Lim; Pier Selenica; Salvatore Piscuoglio; Carol Aghajanian; Larry Norton; Rajmohan Murali; David M Hyman; Laetitia Borsu; Maria E Arcila; Jason Konner; Jorge S Reis-Filho; Roger A Greenberg; Mark E Robson; Nicholas C Turner
Journal:  Clin Cancer Res       Date:  2017-08-01       Impact factor: 12.531

5.  Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer.

Authors:  Ying Jing; Yi Zhang; Hui Zhu; Ke Zhang; Mei-Chun Cai; Pengfei Ma; Peiye Shen; Zhenfeng Zhang; Minghui Shao; Jing Wang; Minhua Yu; Xia Yin; Meiying Zhang; Yuan Hu; Danni Chen; Wen Di; Xiaojie Wang; Guanglei Zhuang
Journal:  Oncogene       Date:  2019-01-07       Impact factor: 9.867

6.  Frameshift Mutations in Repeat Sequences of ANK3, HACD4, TCP10L, TP53BP1, MFN1, LCMT2, RNMT, TRMT6, METTL8 and METTL16 Genes in Colon Cancers.

Authors:  Su Yeon Yeon; Yun Sol Jo; Eun Ji Choi; Min Sung Kim; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2017-08-12       Impact factor: 3.201

7.  Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a "Molecular Second Look".

Authors:  Melissa Schwartz; Olga Camacho-Vanegas; Ashley M Wood; Matthew Dashkoff; Courtney Whitelock; Timothy T Harkins; Carmel J Cohen; Ann Marie Beddoe; Peter Dottino; John A Martignetti
Journal:  Int J Gynecol Cancer       Date:  2018-03       Impact factor: 3.437

Review 8.  Tumor evolution and chemoresistance in ovarian cancer.

Authors:  Soochi Kim; Youngjin Han; Se Ik Kim; Hee-Seung Kim; Seong Jin Kim; Yong Sang Song
Journal:  NPJ Precis Oncol       Date:  2018-09-17

9.  PathFinder: Bayesian inference of clone migration histories in cancer.

Authors:  Sudhir Kumar; Antonia Chroni; Koichiro Tamura; Maxwell Sanderford; Olumide Oladeinde; Vivian Aly; Tracy Vu; Sayaka Miura
Journal:  Bioinformatics       Date:  2020-12-30       Impact factor: 6.937

10.  Mobile element insertions and associated structural variants in longitudinal breast cancer samples.

Authors:  Cody J Steely; Kristi L Russell; Julie E Feusier; Yi Qiao; Sean V Tavtigian; Gabor Marth; Lynn B Jorde
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.